Anti cyclophilin b 11607 1 ap

TA was purchased from Selleckchem (Houston, TX, USA). Antibodies in the present study were derived from the following sources: anti-beclin1 (11306-1-AP), anti-ATG7 (10088-2-AP), anti-acetyl Tubulin (Lys40) (66200-1-Ig), anti-Alpha Tubulin (11224-1-AP), and anti-Cyclophilin B (11607-1-AP), and all secondary antibodies for immunoblot analysis were purchased from Proteintech (RoSDont, IL). Anti-p62 (ab24182, Abcam) was from Abcam (Cambridge, UK). Anti-LC3 (NB100-2220) was obtained from Novus Biologicals. Anti-HDAC6 (7612) and anti-cleaved caspase 3 (9664, CST) were purchased from Cell Signaling Technology (Danvers, MA, USA). Cisplatin was obtained from Sigma (St. Louis, MO, USA).

The antibodies used in this study were as follows: anti‐OGG1 (NB100‐106) and anti‐PINK1 (8E10.1D6) from Novus (Novus Biologicals), anti‐Parkin (sc‐32282) and anti‐TOM20 (sc‐17764) from Santa Cruz, anti‐LC3 (12741), and anti‐BCL2 (3498 S) from CST, anti‐COXIV (ab202554) from Abcam, anti‐α‐tubulin (11224‐1‐AP), anti‐BAX (60267‐1‐Ig), and anti‐cyclophilin B (11607‐1‐AP) from ProteinTech. All the secondary antibodies were purchased from Thermo Fisher Scientific. The specific inhibitor, Th5487, of OGG1 (HY‐125276) was purchased from Med Chem Express.